RNXT übertreffen die 11 der letzten 17Schätzungen.
65%
Nächster Bericht
Datum des nächsten Berichts
30. März 2026
Estimate forQ4 25(Revenue/ EPS)
$456.28K
/
-$0.08
Implizierte Änderung vonQ3 25(Revenue/ EPS)
+71.53%
/
--
Implizierte Änderung vonQ4 24(Revenue/ EPS)
+961.11%
/
-38.46%
RenovoRx, Inc. Common Stock earnings per share and revenue
On 13. Nov. 2025, RNXT reported earnings of -0.08 USD per share (EPS) for Q3 25, beating the estimate of -0.08 USD, resulting in a 1.96% surprise. Revenue reached 266.00 tausend, compared to an expected 413.44 tausend, with a -35.66% difference. The market reacted with a -23.03% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.08 USD, with revenue projected to reach 456.28 tausend USD, implying an increase of 0.00% EPS, and increase of 71.53% in Revenue from the last quarter.
FAQ
What were RenovoRx, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, RenovoRx, Inc. Common Stock reported EPS of -$0.08, beating estimates by 1.96%, and revenue of $266.00K, -35.66% below expectations.
How did the market react to RenovoRx, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -23.03%, changed from $0.97 before the earnings release to $0.75 the day after.
When is RenovoRx, Inc. Common Stock expected to report next?
The next earning report is scheduled for 30. März 2026.
What are the forecasts for RenovoRx, Inc. Common Stock's next earnings report?
Based on 6
analysts, RenovoRx, Inc. Common Stock is expected to report EPS of -$0.08 and revenue of $456.28K for Q4 2025.